Key Point: The incidence of true hepatotoxicity is exceedingly rare across the
statin class. 

Asymptomatic elevations in transaminases are observed in a small percentage of patients.1 Whether transaminase elevation with statin therapy constitutes true hepatotoxicity is unknown; however, progression to liver failure due to statins is exceedingly rare, if it ever occurs1

Reversal of transaminase elevation frequently occurs when the statin dose is reduced. These elevations often do not recur with readministration or when another statin is administered1,2

Moreover, statins have not been shown to worsen the outcome of patients with hepatitis B or C, and treatment of hyperlipidemia may actually improve transaminase elevations in patients with fatty liver condition1

References